Vindesine (Eldisine)

Not approved by the FDA. Approved for use in some countries e.g., U.K., South Africa.

General information

Class/mechanism: Vinca alkaloid, inhibits microtubule formation in the mitotic spindle, causing cell cycle arrest in metaphase.
Route: IV
Extravasation: vesicant

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.

Diseases for which it is used

• Adult T-cell leukemia-lymphoma
• Burkitt lymphoma
• CNS lymphoma
• Diffuse large B-cell lymphoma
• HIV-associated lymphoma
• Non-small cell lung cancer
• Post-transplant lymphoproliferative disorder

Patient drug information

• Vindesine (Eldisine) patient information at Macmillan Cancer Support
• Vindesine (Eldisine) patient information at Genus Pharmaceuticals
• Vindesine (Eldisine) patient drug information (UpToDate)

Also known as

• Code name: LY-099094
• Generic names: desacetylvinblastine amide, DAVA, DVA, VDS
• Brand names: Eldesine, Eldisin, Enison, Fildesin, Gesidine